Guiding Cells to Improve Life
Fate Therapeutics is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular immunotherapeutics for the treatment of severe, life‑threatening diseases. We have built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules, which promote rapid and supra-physiologic activation and inhibition of a cell’s transcriptional program. We are focused on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of cancer, rare genetic diseases and immune disorders.
To accomplish our development objectives, we are applying our cell programming technology to develop three franchises of cellular immunotherapeutics:
Our Immuno-Protection franchise comprises two products, ProHema and ProTmune. ProHema is an ex vivo programmed hematopoietic cellular therapeutic which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic cell transplantation (HCT). ProHema is produced by programming the biological properties of hematopoietic cells of umbilical cord blood ex vivo using the small molecule modulator FT1050 (dmPGE2). This modulation process induces rapid activation of genes involved in the homing, proliferation and survival of hematopoietic stem cells and in the cell cycle, reactivity and anti‑viral properties of T cells. In a Phase 2 interim analysis, these changes resulted in a reduction of severe infection-related adverse events and a reduction in time to neutrophil engraftment. In addition to ProHema, we are developing ProTmune, an ex vivo programmed mobilized peripheral blood therapeutic candidate, and plan to submit an IND to the FDA for this product candidate in 2015.
We are also developing programmed hematopoietic cell-based therapeutics for Immuno-Oncology and Immuno-Regulation. These programs include an “off-the-shelf” adaptive NK cell-based immunotherapeutic with memory-like properties for enhanced persistence, and a CD34+ cell-based immunotherapeutic that has been programmed to express high levels of PD-L1 to induce anergy of auto-reactive T cells.
In addition to the use of small molecules to program cell function, we have developed a proprietary, small-molecule enhanced, induced pluripotent stem cell (iPSC) platform that allows us to program cell fate. Differentiation of iPSCs to therapeutic cells in the hematopoietic lineage, such as T cells and NK cells, holds promise as a potentially disruptive approach for developing next-generation cell-based cancer immunotherapeutics.